Cargando…
Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial
INTRODUCTION: Anti-tumour necrosis factor (TNF) therapy has greatly improved treatment outcomes in patients with inflammatory bowel disease (IBD), but long-term use is associated with cutaneous reactions, susceptibility to infections and frequent injections or hospital visits. Several non-controlled...
Autores principales: | Bouhuys, Marleen, Lexmond, Willem S, Dijkstra, Gerard, Lobatón, Triana, Louis, Edouard, van Biervliet, Stephanie, Groen, Henk, Guardiola, Jordi, van Rheenen, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572401/ https://www.ncbi.nlm.nih.gov/pubmed/34732500 http://dx.doi.org/10.1136/bmjopen-2021-054154 |
Ejemplares similares
-
Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study
por: Smits, L J T, et al.
Publicado: (2020) -
Selecting children with suspected inflammatory bowel disease for endoscopy with the calgranulin C or calprotectin stool test: protocol of the CACATU study
por: Heida, Anke, et al.
Publicado: (2017) -
De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review
por: Bouhuys, Marleen, et al.
Publicado: (2022) -
Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study
por: Paulides, Emma, et al.
Publicado: (2022) -
Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta-analysis
por: Kiss, Szabolcs, et al.
Publicado: (2021)